Laird Harrison July 21, 2022 NEW YORK — Photobiomodulation with low-level red infrared light could improve visual acuity in dry age-related macular degeneration (AMD), clinical researchers say. The treatment, already approved in Europe and parts of Latin America, may be the first to arrest the progress of the disease, said Richard Rosen, MD, DSc (Hon),...
Tag: <span>macular degeneration</span>
Post
Streamlining stem cells to treat macular degeneration
ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE IMAGE: THE DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS INTO RETINAL PIGMENT EPITHELIUM FOR THERAPEUTIC USE TO TREAT ACUTE MACULAR DEGENERATION. THE “SPOTLIGHTS” REPRESENT THE USE OF SINGLE-CELL RNA SEQUENCING TO REVEAL THE GENE EXPRESSION STATE OF CELLS AT EARLY, MID, AND LATE TIME POINTS OF RETINAL PIGMENT EPITHELIUM DIFFERENTIATION. CREDIT:...
Post
Study confirms benefit of supplements for slowing age-related macular degeneration
by National Eye Institute Credit: Pixabay/CC0 Public Domain The Age-Related Eye Disease Studies (AREDS and AREDS2) established that dietary supplements can slow progression of age-related macular degeneration (AMD), the most common cause of blindness in older Americans. In a new report, scientists analyzed 10 years of AREDS2 data. They show that the AREDS2 formula, which...
Post
Researchers make a novel discovery in age-related macular degeneration
by Impact Journals Schematic showing the function(s) of cell adhesion molecules, cytokines, and chemokines. Credit: Aging-US.com A new research paper has been published in Aging (Aging-US), titled “Effect of Humanin G (HNG) on inflammation in age-related macular degeneration (AMD).” Inflammatory processes drive the progression of age-related macular degeneration (AMD) disease—a leading cause of vision loss in the United...
Post
Clinical trial suggests pegcetacoplan may slow onset of age-related macular degeneration
by Bob Yirka, Medical Xpress Picture of the back of the eye showing intermediate age-related macular degeneration. Credit: National Eye Institute An international team of researchers has found via clinical trial that the drug pegcetacoplan may slow the onset of age-related macular degeneration in some people. In their paper published in JAMA Ophthalmology, the group describes...
Post
Implanted chip, natural eyesight coordinate vision in study of macular degeneration
by Emma Yasinski, Stanford University Medical Center In this photo of a study participant’s eye with the implanted chip, the magenta oval shows the size of the beam projected from the glasses onto the retina. Credit: Yannick Le Mer Two years ago, a Stanford researcher and his team showed that with a thin, pixelated chip and...
Post
Macular degeneration can rob you of sight: Know the signs
(HealthDay)—Early diagnosis and care can often stop the progression of age-related macular degeneration (AMD), which is the leading cause of vision loss in older Americans, the American Society of Retina Specialists (ASRS) says. As part of AMD Awareness Month in February, the society urges people to pay attention to their vision and learn more about...
Post
Trigger found for harmful inflammation in lupus, macular degeneration
UNIVERSITY OF VIRGINIA HEALTH SYSTEM IMAGE: JAYAKRISHNA AMBATI, MD, IS PART OF THE UNIVERSITY OF VIRGINIA SCHOOL OF MEDICINE’S DEPARTMENT OF OPHTHALMOLOGY AND THE FOUNDING DIRECTOR OF UVA’S CENTER FOR ADVANCED VISION SCIENCE. CREDIT: COURTESY AMBATI LAB Researchers at the University of Virginia School of Medicine have made a discovery linking lupus, a potentially debilitating...
Post
Toxic DNA buildup in eyes may drive blinding macular degeneration
by University of Virginia Credit: Pixabay/CC0 Public Domain Damaging DNA builds up in the eyes of patients with geographic atrophy, an untreatable, poorly understood form of age-related macular degeneration that causes blindness, new research from the University of Virginia School of Medicine reveals. Based on the discovery, the researchers think it may be possible to treat the disease with common...
Post
First biosimilar approved for macular degeneration, other eye conditions
(HealthDay)—The first biosimilar to Lucentis (ranibizumab injection) has been approved for the treatment of neovascular (wet) age-related macular degeneration and other eye diseases and conditions, the U.S. Food and Drug Administration announced Friday. The approval of the biosimilar, Byooviz (ranibizumab-nuna), is also indicated to treat macular edema after retinal vein occlusion and myopic choroidal neovascularization. Byooviz is...